| Literature DB >> 31922241 |
Shengli Lin1, Pingting Gao1, Quanlin Li1, Yiqun Zhang1, Jianwei Hu1, Mingyan Cai1, Wenzheng Qin1, Lili Ma1, Zhong Ren1, Zhen Zhang1, Xianli Cai1, Liqing Yao1, Weifeng Chen1, Pinghong Zhou1.
Abstract
Achalasia is characterized by impaired swallowing due to lower esophageal sphincter (LES) dysfunction and an increased risk of esophageal carcinoma. Aflatoxin is a known carcinogen. Esophageal retention is relieved by per oral endoscopic myotomy (POEM), which lowers the esophageal cancer risk. The present study determined whether aflatoxin is involved in the pathogenesis of achalasia or esophageal cancer. A total of 75 patients with achalasia were prospectively enrolled from a tertiary center. Aflatoxin levels in their esophageal contents were measured using ELISA, and esophageal mucosal specimens were immunohistochemically evaluated for Ki67 and p53 expression prior to and 3 months after POEM. The effect of aflatoxin on esophageal contractility was assessed using murine specimens. Aflatoxin was detected in 67 patients before POEM and only 2 patients after POEM. The number of Ki67‑ and p53‑immunopositive cells in the esophageal mucosa significantly decreased after POEM: [Ki67: 27.8% (95% confidence interval (CI), 25.98‑29.70) vs. 20.7% (95% CI, 19.78‑24.03), P=0.04 and p53: 2.14% (95% CI, 1.85‑2.41) vs. 1.45% (95% CI, 1.22‑1.68), P=0.03]. In vitro experiments revealed that 500 ng/ml aflatoxin significantly increased the amplitude (P<0.05) and frequency (P<0.05) of spontaneous LES contractions compared with the control group. These increases were blocked by co‑treatment with atropine sulfate (P<0.05), but not with a nitric oxide synthase inhibitor (P>0.05). Aflatoxin was found in most patients with achalasia and was eliminated following POEM. Reduced Ki67 and p53 expression after POEM indicated a decreased risk of carcinogenesis. Aflatoxin accumulation increased LES contractility via cholinergic signaling. Therefore, aflatoxin may maintain achalasia symptoms and increase esophageal cancer risk.Entities:
Year: 2020 PMID: 31922241 PMCID: PMC7002977 DOI: 10.3892/mmr.2020.10914
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Patient characteristics before and after POEM.
| Characteristic | Value |
|---|---|
| Age, years; median [IQR] (range) | 40.00 [26.0–51.0] (14.0–81.0) |
| <18, n (%) | 2.00 (2.7) |
| ≥18 and <60, n (%) | 65.00 (86.7) |
| ≥60, n (%) | 8.00 (10.7) |
| Sex, n (%) | |
| Male | 34.00 (45.3) |
| Female | 41.00 (54.7) |
| Disease duration, years; median [IQR] (range) | 8.00 [4.0–10.0] (0.5–30.0) |
| Sigmoid-type esophagus, n (%) | 9.00 (12) |
| Pretreatment, n (%) | 21.00 (28) |
| Balloon dilatation, n (%) | 9.00 (12) |
| Stent placement, n (%) | 4.00 (5.3) |
| Botox treatment, n (%) | 3.00 (4) |
| Heller myotomy, n (%) | 4.00 (5.3) |
| POEM, n (%) | 4.00 (5.3) |
| Balloon dilatation and POEM, n (%) | 1.00 (1.3) |
| Balloon dilatation and Heller myotomy, n (%) | 1.00 (1.3) |
| Stent and Botox treatment, n (%) | 1.00 (1.3) |
| Duration of POEM, min; median [IQR] (range) | 52.00 [32.0–69.0] (16.0–154.0) |
| Pre-POEM LES pressure, mmHg; median [IQR] (range) | 25.10 [17.3–35.8] (3.9–49.5) |
| Pre-POEM Eckardt score; median [IQR] (range) | 7.00 [6.0–8.0] (4.0–10.0) |
| Pre-POEM aflatoxin, ng/ml; median [IQR] (range) | 13.14 [9.3–15.7] (0.0–36.8) |
| Negative, n (%) | 8.00 (10.7) |
| Positive, n (%) | 67.00 (89.3) |
| Post-POEM LES pressure, mmHg; median [IQR] (range) | 10.1 [8.0–13.2] (5.0–16.2) |
| Post-POEM Eckardt score; median [IQR] (range) | 1.00 [1.0–2.0] (0.0–7.0) |
| Post-POEM aflatoxin, ng/ml; median [IQR] (range) | 0.15 [0.0–0.0] (0.0–6.3) |
| Negative, n (%) | 73.00 (97.3) |
| Positive, n (%) | 2.00 (2.7) |
IQR, interquartile range; POEM, per oral endoscopic myotomy; LES, lower esophageal sphincter.
Figure 1.Fluorescence under 365-nm violet light. (A and B) Aflatoxin- containing samples of retained food exhibited yellow-green fluorescence upon irradiation with 365 nm violet light, while (C and D) control-group samples did not exhibit any fluorescence. Red arrows indicate which sample is being referred to in each panel.
Figure 2.Gastroscopy images of achalasia. (A) Gastroscopy showing food retention and inflammatory edema of the esophageal mucosa in a patient with achalasia at the beginning of the per oral endoscopic myotomy procedure. (B) Gastroscopy showing early esophageal carcinoma in a patient with achalasia; this patient underwent endoscopic submucosal dissection a few weeks later.
Figure 3.Immunohistochemical staining for Ki67 in the esophageal mucosa. Representative micrographs of Ki67 immunohistochemical analysis of specimens taken from patients with achalasia (A) before and (B) after POEM (magnification ×200). (C) Quantification revealed a significant reduction in the percentage of Ki67-positive cells after POEM. *P<0.05, as indicated. POEM, per oral endoscopic myotomy.
Figure 4.Immunohistochemical staining for p53 in the esophageal mucosa. Representative micrographs of p53 immunohistochemical analysis of specimens taken from patients with achalasia (A) before and (B) after POEM (magnification ×200). (C) Quantification revealed a significant reduction in the percentage of p53-positive cells after POEM. *P<0.05, as indicated. POEM, per oral endoscopic myotomy.
Figure 5.Amplitude and frequency under different levels of aflatoxin. Aflatoxin treatment increases the (A) amplitude and (B) frequency of murine lower esophageal sphincter contractions. Data are expressed as mean ± standard error of the mean. *P<0.05 vs. control.
Figure 6.Amplitude and frequency under different types of solutions. (A) Amplitude and (B) frequency of murine LES contractions after the bath application of AF alone and with ATR or the nitric oxide synthase inhibitor l-NNA. The bath application of ATR (0.2 µg/ml) significantly inhibited the (A) amplitude and (B) frequency of LES contractions in the presence of AF. However, the same dose of l-NNA had no such effect. Data were expressed as mean ± standard error of the mean. *P<0.05 vs. control; #P<0.05 vs. AF. LES, lower esophageal sphincter; AF, aflatoxin; ATR, atropine sulfate; l-NNA, NG-nitro-l-arginine.